Liver Support Systems for Acute Liver Failure Lack Strong Evidence of Efficacy, Review Finds

Despite their use in critical care settings, liver support systems—devices designed to temporarily assist liver function in patients with acute liver failure—show unclear benefits, according to a comprehensive review of 11 studies published through 2019. The findings, from a meta-analysis, highlight significant gaps in evidence regarding their impact on mortality, complications, and transplant needs.

What Are Liver Support Systems?

Liver support systems are therapeutic devices used to filter toxins and support metabolic functions in patients with acute liver failure (ALF), a life-threatening condition marked by rapid loss of liver function. ALF often results from drug overdoses, viral infections, or alcohol toxicity, and can lead to hepatic encephalopathy, multi-organ failure, and death. Two types exist: artificial systems, which use synthetic materials to remove toxins, and bioartificial systems, which incorporate living liver cells. However, none of the bioartificial liver support systems are available on the market.

What Do Recent Studies Say?

The analysis included 681 patients, with results showing no clear reduction in 28-day mortality, liver transplantation rates, or serious adverse effects. The studies, conducted between 1973 and 2019, were small, often single-center, and varied in design. "The lack of high-quality trials limits our ability to draw definitive conclusions," the authors wrote.

Why Is the Evidence So Limited?

Several factors contribute to the uncertainty. Many studies were published in abstract form rather than full papers, and most were conducted before 2019. Additionally, the devices tested were produced by small manufacturers with limited market presence. The review noted that “most liver support systems used in trials are no longer in clinical use,” complicating efforts to assess their modern relevance. Industry funding was reported in four studies, raising questions about potential biases.

What Are the Alternatives to Liver Support Systems?

Standard care for ALF includes managing complications, such as cerebral edema and infections, while awaiting liver transplantation. For patients with drug-induced ALF, N-acetylcysteine (NAC) is a proven treatment for acetaminophen overdose. However, no specific therapies exist for other causes, leaving liver support systems as an experimental option.

What’s Next for Research?

As of July 2025, no ongoing trials are evaluating liver support systems for ALF, according to the review. Researchers emphasize the need for large, randomized controlled trials to address key questions about safety and efficacy. “Future studies should standardize outcome measures and include diverse patient populations,” the authors recommended. Until then, the use of these devices remains controversial, with guidelines advising caution.